SIRT2 is a Tumor Suppressor That Connects Aging, Acetylome, Cell Cycle Signaling, and Carcinogenesis

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2012 Sep 4

PMID 22943040

Citations 52

Authors

Seong-Hoon Park

Yuming Zhu

Ozkan Ozden

Hyun-Seok Kim

Haiyan Jiang

Chu-Xia Deng

David Gius

Athanassios Vassilopoulos

Affiliations

Soon will be listed here.

Abstract

One long standing observation in clinical oncology is that age increase is the single most statistically significant factor/variable that predicts for the incidence of solid tumors. This observation suggests that the cellular and molecular processes and mechanisms that direct an organism's life span may be used to determine the clinical connection between aging and carcinogenesis. In this regard, the genes that impact upon longevity have been characterized in S. cerevisiae and C. elegans, and the human homologs include the Sirtuin family of protein deacetylases. We have recently shown that the primary cytoplasmic sirtuin, Sirt2 appears to meet the criteria as a legitimate tumor suppressor protein. Mice genetically altered to delete Sirt2 develop gender-specific tumorigenesis, with females primarily developing mammary tumors, and males developing multiple different types of gastrointestinal malignancies. Furthermore human tumors, as compared to normal samples, displayed significant decreases in SIRT2 levels suggesting that SIRT2 may also be a human tumor suppressor.

Citing Articles

Molecular Sentinels: Unveiling the Role of Sirtuins in Prostate Cancer Progression.

Chouhan S, Muhammad N, Usmani D, Khan T, Kumar A Int J Mol Sci. 2025; 26(1.

PMID: 39796040 PMC: 11720558. DOI: 10.3390/ijms26010183.

The role of NAD-dependent deacetylase sirtuin-2 in liver metabolic stress through regulating pyruvate kinase M2 ubiquitination.

Guo J, Nie J, Li D, Zhang H, Zhao T, Zhang S J Transl Med. 2024; 22(1):656.

PMID: 39004743 PMC: 11247741. DOI: 10.1186/s12967-024-05435-w.

Recent Advances in PROTACs for Drug Targeted Protein Research.

Yao T, Xiao H, Wang H, Xu X Int J Mol Sci. 2022; 23(18).

PMID: 36142231 PMC: 9499226. DOI: 10.3390/ijms231810328.

Nicotinamide riboside alleviates cisplatin-induced peripheral neuropathy via SIRT2 activation.

Acklin S, Sadhukhan R, Du W, Patra M, Cholia R, Xia F Neurooncol Adv. 2022; 4(1):vdac101.

PMID: 35875690 PMC: 9297957. DOI: 10.1093/noajnl/vdac101.

Detachment of Hexokinase II From Mitochondria Promotes Collateral Sensitivity in Multidrug Resistant Chronic Myeloid Leukemia Cells.

Oliveira T, Lemos D, Jean L, Kawashima J, de Azevedo V, Salustiano E Front Oncol. 2022; 12:852985.

PMID: 35719932 PMC: 9204307. DOI: 10.3389/fonc.2022.852985.

References

Hallows W, Albaugh B, Denu J . Where in the cell is SIRT3?--functional localization of an NAD+-dependent protein deacetylase. Biochem J. 2008; 411(2):e11-3. PMC: 3313448. DOI: 10.1042/BJ20080336. View

Rothgiesser K, Erener S, Waibel S, Luscher B, Hottiger M . SIRT2 regulates NF-κB dependent gene expression through deacetylation of p65 Lys310. J Cell Sci. 2010; 123(Pt 24):4251-8. DOI: 10.1242/jcs.073783. View

Afshar G, Murnane J . Characterization of a human gene with sequence homology to Saccharomyces cerevisiae SIR2. Gene. 1999; 234(1):161-8. DOI: 10.1016/s0378-1119(99)00162-6. View

Inoue T, Nakayama Y, Yamada H, Li Y, Yamaguchi S, Osaki M . SIRT2 downregulation confers resistance to microtubule inhibitors by prolonging chronic mitotic arrest. Cell Cycle. 2009; 8(8):1279-91. DOI: 10.4161/cc.8.8.8245. View

Gius D, Cui H, Bradbury C, Cook J, Smart D, Zhao S . Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. Cancer Cell. 2004; 6(4):361-71. DOI: 10.1016/j.ccr.2004.08.029. View

Knudson Jr A . Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971; 68(4):820-3. PMC: 389051. DOI: 10.1073/pnas.68.4.820. View

Inoue T, Hiratsuka M, Osaki M, Yamada H, Kishimoto I, Yamaguchi S . SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress. Oncogene. 2006; 26(7):945-57. DOI: 10.1038/sj.onc.1209857. View

Hiratsuka M, Inoue T, Toda T, Kimura N, Shirayoshi Y, Kamitani H . Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. Biochem Biophys Res Commun. 2003; 309(3):558-66. DOI: 10.1016/j.bbrc.2003.08.029. View

North B, Verdin E . Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during mitosis. PLoS One. 2007; 2(8):e784. PMC: 1949146. DOI: 10.1371/journal.pone.0000784. View

10.

Tao R, Coleman M, Pennington J, Ozden O, Park S, Jiang H . Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. Mol Cell. 2010; 40(6):893-904. PMC: 3266626. DOI: 10.1016/j.molcel.2010.12.013. View

11.

Yang X . Lysine acetylation and the bromodomain: a new partnership for signaling. Bioessays. 2004; 26(10):1076-87. DOI: 10.1002/bies.20104. View

12.

Kouzarides T . Chromatin modifications and their function. Cell. 2007; 128(4):693-705. DOI: 10.1016/j.cell.2007.02.005. View

13.

Guarente L . Sir2 links chromatin silencing, metabolism, and aging. Genes Dev. 2000; 14(9):1021-6. View

14.

Hunter T . Oncoprotein networks. Cell. 1997; 88(3):333-46. DOI: 10.1016/s0092-8674(00)81872-3. View

15.

Sherr C, McCormick F . The RB and p53 pathways in cancer. Cancer Cell. 2002; 2(2):103-12. DOI: 10.1016/s1535-6108(02)00102-2. View

16.

Wang R, Sengupta K, Li C, Kim H, Cao L, Xiao C . Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell. 2008; 14(4):312-23. PMC: 2643030. DOI: 10.1016/j.ccr.2008.09.001. View

17.

Kim E, Kho J, Kang M, Um S . Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity. Mol Cell. 2007; 28(2):277-90. DOI: 10.1016/j.molcel.2007.08.030. View

18.

North B, Verdin E . Sirtuins: Sir2-related NAD-dependent protein deacetylases. Genome Biol. 2004; 5(5):224. PMC: 416462. DOI: 10.1186/gb-2004-5-5-224. View

19.

Land H, Parada L, Weinberg R . Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature. 1983; 304(5927):596-602. DOI: 10.1038/304596a0. View

20.

Bell E, Emerling B, Ricoult S, Guarente L . SirT3 suppresses hypoxia inducible factor 1α and tumor growth by inhibiting mitochondrial ROS production. Oncogene. 2011; 30(26):2986-96. PMC: 3134877. DOI: 10.1038/onc.2011.37. View